AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Verve Therapeutics Soars 23.31% on Promising Gene-Editing Trial Data
Generated by AI AgentAinvest Movers Radar
Monday, Apr 14, 2025 8:48 am ET1min read
On April 14, 2025, Verve Therapeutics' stock surged by 23.31% in pre-market trading, driven by promising early-stage trial data for its gene-editing therapy.
Verve Therapeutics reported encouraging results from its early-stage study, where a single infusion of VERVE-102 led to significant reductions in blood PCSK9 and LDL-C levels. The mean reduction in LDL-C was 53%, with a maximum reduction of 69%. This therapy employs Verve's proprietary GalNAc-LNP delivery technology, designed to permanently disable the PCSK9 gene in the liver, leading to sustained cholesterol reduction.
The ongoing trial investigates VERVE-102 as a single-course treatment aimed at permanently inactivating the PCSK9 gene, which is a key regulator of cholesterol metabolism. The positive initial data from the Heart-2 Phase 1b clinical trial has bolstered investor confidence in the company's innovative approach to treating high cholesterol.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Two Harbors (TWO) Surges 1.59% to Monthly High Amid Anticipation of $1.3B UWM Acquisition
Dec.19 2025
Trane Technologies Surges 1.46% on Q3 Earnings, Analysts Target $550
Dec.19 2025
Rivian (RIVN) Surges 27.34% on Analyst Upgrades, Q3 Revenue Growth Drives Rebound
Dec.19 2025
Tata Chemicals Share Price Soars 119.32% on Novabay Acquisition Drive
Dec.19 2025
X3 Holdings (XTKG) Rallies 36.76% Intraday, 22.50% in Three Sessions on Technical Rebound and Speculative Buying
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet